Our Network Imfinzi approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery Tags: #Research #R&D #Oncology #AstraZeneca Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone.